Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics

Academic Radiology
Richard G AbramsonCarlos L Arteaga

Abstract

Response Evaluation Criteria in Solid Tumors (RECIST) is a standardized methodology for determining therapeutic response to anticancer therapy using changes in lesion appearance on imaging studies. Many radiologists are now using RECIST in their routine clinical workflow, as part of consultative arrangements, or within dedicated imaging core laboratories. Although basic RECIST methodology is well described in published articles and online resources, inexperienced readers may encounter difficulties with certain nuances and subtleties of RECIST. This article illustrates a set of pitfalls in RECIST assessment considered to be "beyond the basics." These pitfalls were uncovered during a quality improvement review of a recently established cancer imaging core laboratory staffed by radiologists with limited prior RECIST experience. Pitfalls are presented in four categories: (1) baseline selection of lesions, (2) reassessment of target lesions, (3) reassessment of nontarget lesions, and (4) identification of new lesions. Educational and operational strategies for addressing these pitfalls are suggested. Attention to these pitfalls and strategies may improve the overall quality of RECIST assessments performed by radiologists.

References

Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy J ErasmusReginald F Munden
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J Byrne, A K Nowak
Mar 20, 2008·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Chikako SuzukiLennart Blomqvist
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lori E DoddMargaret M Mooney
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Oct 29, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas E Yankeelov, John C Gore
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tony S K Mok
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Jun 23, 2010·AJR. American Journal of Roentgenology·Tracy A JaffeDaniel C Sullivan
Jun 23, 2010·AJR. American Journal of Roentgenology·Tracy A JaffeDaniel C Sullivan
Jul 24, 2010·AJR. American Journal of Roentgenology·Mizuki NishinoAnnick D Van den Abbeele
Jun 30, 2012·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Aaron C AbajianDaniel L Rubin

❮ Previous
Next ❯

Citations

Nov 29, 2015·Magnetic Resonance Imaging Clinics of North America·Richard G AbramsonThomas E Yankeelov
May 31, 2020·Annals of Surgical Oncology·Daan Jan Willem RauwerdinkGenevieve Marie Boland
Jan 1, 2019·Visual Computing for Industry, Biomedicine and Art·Bin ZhengGopichandh Danala
Jun 11, 2020·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Thomas BeyerOsama Mawlawi
Dec 8, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Corinne Faivre-FinnScott J Antonia
Apr 1, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Joo Hyun ORichard L Wahl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.